EUVIMEDEUVIMED entdecken
Crossref

Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy

Yanjuan Huang, Yike Li iD, Ziwei Han, Jinqi Deng, Shaokun Dong, Wenxing Lv, Chao Liu, Lele Li iD, Shuo Wan, Jiashu Sun iD

Nano Letters · 2025

DOI: 10.1021/acs.nanolett.5c04265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Yanjuan Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center …. Hauptthemen laut MEDLINE: Iron, Manganese, Immunotherapy, Nucleotides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metalloimmunotherapy represents a new paradigm in cancer immunotherapy by leveraging the immune-modulatory functions of metal ions, either alone or in combination with agonists. However, the low bioavailability of free metal ions and agonists limits robust stimulation of antitumor immune responses. Here we developed multivalent metal-nucleotide nanoagonists (Mn-MNAs) through aqueous coordination of multiple nucleotide-based innate immune agonists with Fe2+ and Mn2+, which not only enhanced the stability and cellular uptake of the agonists but also amplified the antitumor immunity by concurrently activating the stimulator of interferon genes (STING) and toll-like receptor 9 (TLR9) pathways. Intratumoral injection of Mn-MNAs significantly inhibited tumor growth and fostered an immune-supportive tumor microenvironment in the CT26 tumor model. Intravenous administration of Mn-MNAs achieved remarkable therapeutic efficacy in the B16F10 melanoma model, which was further enhanced upon combination with a checkpoint blockade. Overall, multivalent nanoagonists open new avenues for cancer metalloimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IronManganeseImmunotherapyNucleotidesImmunity, InnateColonic NeoplasmsMelanoma, ExperimentalAnimalsMiceCell Line, TumorMice, Inbred BALB CTumor MicroenvironmentSignal Transduction

Stichwörter der Autor:innen

cancer metalloimmunotherapycoordinationinnate immune activationmetal−nucleotidenanoagonists

Substanzen

IronManganeseNucleotides

Autor:innen und Institutionen

  • Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing 100190, China.
  • School of Future Technology, University of Chinese Academy of Sciences, Beijing 100049, China.
  • Foundation for Applied Molecular Evolution, Alachua, Florida 32615, United States.

ORCID-Profile: Yike Li, Lele Li, Jiashu Sun

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences

Zitieren

APA

Huang, Y., Li, Y., Han, Z., Deng, J., Dong, S., Lv, W., Liu, C., Li, L., Wan, S., & Sun, J. (2025). Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c04265

Vancouver

Huang Y, Li Y, Han Z, Deng J, Dong S, Lv W, et al. Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c04265

BibTeX
@article{Huang2025,
  author = {Huang, Yanjuan and Li, Yike and Han, Ziwei and Deng, Jinqi and Dong, Shaokun and Lv, Wenxing and Liu, Chao and Li, Lele and Wan, Shuo and Sun, Jiashu},
  title = {Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy},
  journal = {Nano Letters},
  year = {2025},
  doi = {10.1021/acs.nanolett.5c04265}
}
Kostenlos starten →